PROGNOSTIC INDICATORS IN HORMONE REFRACTORY PROSTATE CANCER

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1997 • 1,621 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Classification of prostatic carcinomas.

1966 • 1,101 citations

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1988 • 618 citations

Prostate Specific Antigen in the Preoperative and Postoperative Evaluation of Localized Prostatic Cancer Treated with Radical Prostatectomy

1988 • 597 citations

Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies

1972 • 449 citations

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 • 400 citations

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

1994 • 225 citations

A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.

1998 • 224 citations

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.

1998 • 223 citations

The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer

1992 • 175 citations

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.

1994 • 157 citations

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study

1996 • 147 citations

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy

1993 • 140 citations

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

1979 • 140 citations

Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate Cancer

1991 • 138 citations

Prognostic factors in patients with advanced stage prostate cancer.

1985 • 123 citations

Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group

1991 • 120 citations

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome.

1988 • 114 citations

Multivariate Analysis of Prognostic Factors in Patients with Advanced Prostatic Cancer: Results from 2 European Organization for Research on Treatment of Cancer Trials

1989 • 111 citations

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.

1995 • 101 citations

A phase ii trial of oral estramustine and oral etoposide in hormone refractory prostate cancer

1997 • 100 citations

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1992 • 95 citations

Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma

1997 • 84 citations

Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer

1998 • 83 citations

Critical analysis of the ability of the endorectal coil magnetic resonance imaging scan to predict pathologic stage, margin status, and postoperative prostate-specific antigen failure in patients with clinically organ-confined prostate cancer.

1996 • 80 citations

Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.

1995 • 73 citations

Staging prostate cancer with MR imaging: a combined radiologist-computer system.

1997 • 73 citations

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

1990 • 72 citations

Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance

1979 • 62 citations

Staging of prostatic cancer: accuracy of MR imaging.

1995 • 61 citations

Nuclear bone imaging in metastatic cancer of the prostate

1981 • 60 citations

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy

1992 • 58 citations

An Exponential Model Relating Censored Survival Data and Concomitant Information for Prostatic Cancer Patients2

1974 • 53 citations

A comparative clinical trial of adriamycin and 5‐fluorouracil in advanced prostatic cancer: Prognostic factors and response

1983 • 48 citations

Systemic Treatment of Advanced Prostatic Cancer: Development of a New System for Defining Response

1981 • 47 citations

Prognostic factors in patients with advanced prostate cancer

1989 • 46 citations

Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease

1996 • 42 citations

Tumor Marker Doubling Time in Patients with Prostate Cancer: Determination of Prostate-Specific Antigen and Prostatic Acid Phosphatase Doubling Time

1995 • 41 citations

Current status of intermittent androgen suppression in the treatment of prostate cancer

1998 • 39 citations

Prostate‐specific Antigen and other Prognostic Factors in Patients with Hormone‐resistant Prostatic Cancer Undergoing Experimental Treatment

1992 • 36 citations

European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976—1996

1998 • 31 citations

PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.

1997 • 29 citations

METASTASES IN BONE MARROW AND MYELOPHTHISIC ANEMIA FROM CARCINOMA OF THE PROSTATE

1949 • 29 citations

Assessment of hormone refractory prostate cancer

1997 • 27 citations

Carcinoma of prostate correlation between radiologic quantitation of metastases and patient survival

1975 • 27 citations

Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease

1993 • 23 citations

Comparison of treatments for prostatic cancer using an exponential-type life model relating survival to concomitant information.

1974 • 16 citations

Acid phosphatase: defining a role in androgen-independent prostate cancer

1996 • 15 citations

Symptomatology of metastatic prostate cancer: prognostic significance

1994 • 11 citations

Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer

1996 • 9 citations

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatc cancer: A trial with 10-ethyl-deaza-aminopterin

1994 • 8 citations

Alkaline phosphatase in serum of patients with prostatic carcinoma

1977 • 3 citations

Deleted Work

1955 • 0 citations

Cited By (0)

Loading...